免疫监视
免疫系统
多发性骨髓瘤
趋化因子
CD14型
生物
细胞毒性T细胞
免疫学
趋化因子受体
骨髓
癌症研究
肿瘤微环境
体外
遗传学
作者
Oksana Zavidij,Nicholas J. Haradhvala,Tarek H. Mouhieddine,Romanos Sklavenitis‐Pistofidis,Songjie Cai,Mairéad Reidy,Mahshid Rahmat,Abdallah Flaifel,Benjamin Ferland,Nang Kham Su,Michael P. Agius,Jihye Park,Salomon Manier,Mark Bustoros,Daisy Huynh,Marzia Capelletti,Brianna Berrios,Chia‐Jen Liu,Meng Xiao He,Esteban Braggio
出处
期刊:Nature cancer
[Springer Nature]
日期:2020-04-27
卷期号:1 (5): 493-506
被引量:331
标识
DOI:10.1038/s43018-020-0053-3
摘要
Precursor states of multiple myeloma (MM) and its native tumor microenvironment need in-depth molecular characterization to better stratify and treat patients at risk. Using single-cell RNA sequencing of bone marrow cells from precursor stages, monoclonal gammopathy of unknown significance and smoldering MM, to full-blown MM alongside healthy donors, we demonstrate early immune changes during patient progression. We find that natural killer cell abundance is frequently increased in the early stages and associated with altered chemokine receptor expression. As early as smoldering MM, we show loss of granzyme K+ memory cytotoxic T cells and show their critical role in MM immunosurveillance in mouse models. Finally, we report major histocompatibility complex class II dysregulation in CD14+ monocytes, which results in T-cell suppression in vitro. These results provide a comprehensive map of immune changes at play over the evolution of premalignant MM, which will help develop strategies for immune-based patient stratification. Ghobrial, Getz and colleagues characterize the changes in the tumor immune microenvironment associated with multiple myeloma progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI